• Previously untreated with histological confirmation of AML by World Health Organization 2022 criteria and are ineligible for treatment with a standard cytarabine and anthracycline induction regimen due to age, or comorbidity.

• Participant has any level of CD123 expression on blasts.

• Participants must be considered ineligible for intensive chemotherapy, defined by the following:

‣ ≥75 years of age; or

⁃ ≥18 to 74 years of age with at least 1 of the following:

• Eastern Cooperative Oncology Group (ECOG) performance status of 2 or 3.

∙ Diffusing capacity of the lung for carbon monoxide of ≤65% or forced expiratory volume in 1 second ≤65%.

∙ Baseline creatinine clearance ≥30 to \<45 milliliters/minute calculated by the Cockcroft Gault formula or measured by 24-hour urine collection.

∙ Hepatic disorder with total bilirubin \>1.5 x upper limit of normal.

∙ Any other condition for which the physician judges the participant to be unsuitable for intensive chemotherapy.

• ECOG performance status:

‣ 0 to 2 for participants ≥75 years of age, or

⁃ 0 to 3 for participants ≥18 to 74 years of age.